摘要
目的 观察卡维地洛治疗围生期心肌病的疗效。方法 18例围生期心肌病患者，经其他常规抗心力衰竭治疗基础上，给予卡维地洛（达利全）治疗。卡维地洛从3．125mg，每天2次开始，根据血压、心率每2周上调1次直至靶剂量或耐受剂量，每半年和1年到门诊行超声心动图检查随访疗效。结果 共随访6—36个月，平均15．1±10．3个月，18例患者死亡1例，失访3例。与治疗前比，14例患者治疗后左室舒张末径明显缩小（51±5ram vs 60±8mm），射血分数明显提高（0．56±0．05vs0．38±0．12）（P〈0．05），心功能改善了2级以上。卡维地洛的平均剂量为11．8±9．3mg（6．25—25mg），每天2次，无明显不良反应发生。结论 卡维地洛可明显改善围生期心肌病患者的心功能。
Objective The curative effect of carvedilol in 18 patients with peripartum cardiomyopathy. Methods Carvedilol was prescribed in 18 patients with peripartum cardiomyopathy , from low dosage （3. 125mg bid） ,and up-titrated till target dosage of 25 mg bid or maximal tolerance dosage in interval of two weeks when heart failure was controlled. We followed up these patients in outpatient. Before and after treatment with carvedilol, heart function , left ventricular distolic dimension and ejection fraction were performed. Results After treatment with carvedilol , heart function was attained NYHA class Ⅱ, left ventricular distolic dimension was shortend and ejection fraction was improved significantly （51 ± 5 mm vs 60 ± 8 mm, 0.56 ±0.05 vs 0.38 ±0.12 P 〈 0.05 ）. Carvedilol average dosage was 11.8 ±9.3 mg.（6.25-25 mg） , side effect were not observed. Conclusion Carvedilol is effective to treat peripartum cardiomyopathy.
出处
《中国医刊》
CAS
2007年第4期27-28,共2页
Chinese Journal of Medicine
关键词
卡维地洛
围生期心肌病
Carvedilol
peripartum cardiomyopathy
